Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

o. At 2 hours post-dose, 16.1% of patients taking ADX10059 were pain-free compared to 4.5% taking placebo (p = 0.039). A benefit of ADX10059 on migraine pain could be seen from 1 hour after dosing, with the compound being numerically superior to placebo at 1.0 and 1.5 hours post-dose. The magnitude of active versus placebo response at 2 hours (3.6 fold for pain-free and 1.6-fold for mild/no pain) was similar to that seen in the acute treatment migraine trials for the triptans (see ref. 1 below). In addition, there were trends to superiority for ADX10059 over placebo for migraine pain improvement (mild or no pain) at all time points up to two hours post-dosing. For other secondary efficacy endpoints there were no statistically significant differences between the two dose groups.

"The study results show an important and novel principle in the treatment of migraine with the positive outcome using an mGluR5 receptor modulator. The data offer the real prospect of development of a completely new class of medicines that modulate the effects of glutamate and thus offer a neural - nerve-based - therapy for migraine sufferers," commented Professor Peter Goadsby, Institute of Neurology, Queen Square London, and Department of Neurology, University of San Francisco, California.

"These results are the first demonstration of the involvement of mGluR5 in the migraine process," said Dr Vincent Mutel, CEO of Addex. "We believe that ADX10059 could play a significant role in the long term management of this disease, and have given the green light to initiate a Phase IIb trial."

About Migraine

Migraine is a condition characterized by recurrent episodes of headache accompanied by a variety of other symptoms such as nausea, light and sound sensitivity, and fatigue. Attacks may be preceded by aura (usually visual phenomena such as flashing lights, zigzag lines and loss of visual fields) in about 40% of patients. An average migraine patient suffers 12 attacks a y
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:4/27/2015)... 27, 2015 TWi Pharmaceuticals, Inc. ("TWi") ... Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda ... Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to ... to TWi,s generic dexlansoprazole delayed release capsules for ... dosage strengths. An Abbreviated New Drug Application for TWi,s ...
(Date:4/25/2015)...  With the introduction of Elekta,s new Leksell Gamma ... now available for more patients with a wider variety ... radiosurgery system for the brain, integrates advanced motion management, ... of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma Knife ... in Barcelona . "This ...
(Date:4/24/2015)... , April 24, 2015  Perrigo Company plc ("Perrigo" ... rejection of the unsolicited offer from Mylan NV ("Mylan") ... outstanding shares of Perrigo for $60.00 per share in ... Perrigo share (the "Offer").  The Board ... share significantly undervalued the Company and its future growth ...
Breaking Medicine Technology:TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4
... Medical Design Excellence Awards has announced the ... Lifetime Achievement Award .  This award honors an individual ... demonstrable impact on technological, business, and cultural advancements in ... Selected by the entire UBM Canon Medical Content ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... call and a live Internet webcast along with a slide ... (7:00 a.m. PT) to discuss results for the 2011 first ... call is (877) 295-5743, confirmation code 63195016.  International ...
Cached Medicine Technology:UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award 2UBM Canon and Medical Design Excellence Awards (MDEA) Announce Winner of Lifetime Achievement Award 3Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011 2
(Date:4/27/2015)... April 27, 2015 The WeedLife ... to a problem that has been troubling cannabis ... campaigns: by announcing the launch of WeedLIVE, ... kind. , Officially launched today, WeedLIVE.com is ... created to index only marijuana-related business websites. , ...
(Date:4/27/2015)... 2015 Winscribe Professional for Windows ... of mobile speech productivity technology, which also includes ... smartphones. , Winscribe has supported mobile ... 2005. With the latest enhancement, Winscribe Professional ... application interface in the last ten years. ...
(Date:4/27/2015)... 2015 Cambia Health Solutions ... joined its team as Operating Partner within its ... investing in and building companies that change the way ... role, Albert will be responsible for accelerating Cambia’s investments, ... it is both economically sustainable and person-focused, while looking ...
(Date:4/27/2015)... Covenant Care, a leading post acute ... its “Enhanced Dining” service with two primary focuses: ... from residents, patients and families to ensure that their ... its dining rooms so that they are more homelike, ... for our residents is our number one priority and ...
(Date:4/27/2015)... 27, 2015 Jvion, the Atlanta-based leader ... Pacesetter and recognized as one of the top 40 ... which is presented by the Atlanta Business Chronicle, honors ... Atlanta’s status as an economic capital and employment hub. ... is spurred by the growing need to improve healthcare ...
Breaking Medicine News(10 mins):Health News:The WeedLife Network debuts its ground-breaking WeedLIVE cannabis industry search engine 2Health News:The WeedLife Network debuts its ground-breaking WeedLIVE cannabis industry search engine 3Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 2Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 3Health News:Winscribe Professional Dictation for Smartphones Evolves as Microsoft’s Mobile OS Grows 4Health News:Cambia Welcomes Ben Albert as Operating Partner 2Health News:Cambia Welcomes Ben Albert as Operating Partner 3Health News:Covenant Care Rolls Out "Enhanced Dining" Offering Restaurant Style Experience To Residents, Patients & Families 2Health News:Jvion Named to Top 40 Atlanta 2015 Pacesetters 2
... , , ... provider of cardiovascular technologies, announced today at the Transcatheter Cardiovascular ... Food and Drug Administration has cleared the company,s MEGA(TM) ... 50cc IAB with a true 8Fr. shaft, the MEGA has ...
... DETROIT, Sept. 23 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... Georges Ugeux resigned as a director of the Company and from ... was the chairman of the independent committee. , , ... disagreements with the majority shareholder and senior management of the Company ...
... , NEW YORK, Sept. 23 The Michael ... research to successfully translate neurotrophic factor advances from pre-clinical and ... disease. The funding will be awarded under a new Directed ... , , The Foundation,s intention is ...
... , , , CAMDEN, N.J., Sept. 23 ... a result of a Consent Order agreed to by the parties in ... , In an agreement reached in the United States District ... their methodologies when making claims about top docs. In addition, they agree ...
... all agree, though, that biggest risk factor is the brain ... way to reduce the chances of developing dementia such as ... stroke by concentrating on all the known stroke risk factors, ... from an analysis of 30 previous studies that involved more ...
... City, Utah) University of Utah College of Nursing faculty ... Business Magazine today as one of its 2009 Health ... within the health care,system and contributes to continuously improving ... took place at the Grand America Hotel located in ...
Cached Medicine News:Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 2Health News:MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors 3Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2Health News:Virtua's 'Top Docs' Ad Campaign Survives Cooper's Law Suit 2Health News:Preventing Second Stroke May Stave Off Dementia 2Health News:Preventing Second Stroke May Stave Off Dementia 3Health News:U. College of Nursing's Kathie Supiano a 'health care hero' 2
... provides optimum flow rate for ... on any voltage worldwide. Optical ... Interlock and easy load head. ... Spike Tubing, Dual Pneumatic Foot ...
... Device uses a 2-mm reciprocating movement at 4000 ... the cannula in tissue. So less force is ... That makes the lipoplasty procedure easier on both ... to learn that the PAL® is not ultrasonic. ...
... The next generation of ... new PSI-TEC III retains all ... made PSI-TEC a leading name ... maximum flow,vacuum pumps for high ...
Richardson Blade - for use with Bookler Universal Table Mounted Retractor Systems...
Medicine Products: